Leslie B. Tyson

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Vincent A. Miller, Mark G. Kris, Jyoti D. Patel et al. · Journal of Clinical Oncology · 2004 · 746 citations

Medicine, Oncology, Pharmacology +16

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

Mark G. Kris, Richard J. Gralla, R A Clark et al. · Journal of Clinical Oncology · 1985 · 341 citations

Medicine, Pharmacology, Pharmacotherapy +17

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Gregory J. Riely, Mark G. Kris, Binsheng Zhao et al. · Clinical Cancer Research · 2007 · 284 citations · Full text

Medicine, Oncology, Pharmacology +16

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

Mark G. Kris, Richard J. Gralla, Leslie B. Tyson et al. · Journal of Clinical Oncology · 1989 · 240 citations

Medicine, Pharmacology, Pharmacotherapy +16

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients

Mark G. Kris, Richard J. Gralla, Leslie B. Tyson et al. · Cancer · 1985 · 196 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15